CX 2019 Presentations
Please note: Some presentations may not be available as permission may not have been given to publish. Sometimes this will include a debate session, during which one speaker has given permission but another speaker has denied it, resulting in the entire session not being uploaded to the website.
Peripheral Proximal Arterial Ischaemia Challenges - Tuesday, 16th April
Venue: Upper Main Auditorium
Time: 08:00 - 18:00
Peripheral arterial disease issues
| Chairing: | Cliff Shearman, Southampton, United Kingdom |
| Moderator: | Barry Katzen, Miami, United States |
Time: 08:00 - 08:08
Treatment of claudication is aimed to increase walking distance, improve quality of life and prevent cardiovascular events by reducing risk factors
| Speaker: | Sanne Klaphake, Rotterdam, Netherlands |
Time: 08:08 - 08:16
Female gender is a risk factor for poor outcomes after revascularisation for peripheral arterial disease
| Speaker: | Ruth Benson, Birmingham, United Kingdom |
Time: 08:24 - 08:32
Office-based lower extremity arterial interventions are feasible, safe, cost-effective and patients love it
| Speaker: | Enrico Ascher, Brooklyn, United States |
Time: 08:32 - 08:40
Ambulatory treatment of arterial disease - European perspective
| Speaker: | Yann Gouëffic, Nantes, France |
Time: 08:48 - 08:56
Appropriate follow-up of patients after endovascular procedures
| Speaker: | Marianne Brodmann, Graz, Austria |
Time: 08:56 - 09:04
Open or endovascular repair for popliteal artery aneurysms - A case-control study
| Speaker: | Martin Björck, Uppsala, Sweden |
Imaging
| Chairing: | Robert Morgan, President CIRSE, London, United Kingdom |
| Moderator: | Andrew Holden, Auckland, New Zealand |
Time: 09:12 - 09:20
Assessment of the perfusion with indocyanine green fluorescence imaging (ICG-FI) before and after revascularisation tells the success of revascularisation
| Speaker: | Maarit Venermo, Helsinki, Finland |
Time: 09:20 - 09:28
Tips and tricks to optimise CO2 angiography (including work-up with no-contrast MR angiography)
| Speaker: | Jos van den Berg, Lugano, Switzerland |
Time: 09:36 - 09:44
IVUS sizing improves outcomes of DCB therapy in the femoropopliteal segment
| Speaker: | Phillip Puckridge, Marion, Australia |
Time: 09:44 - 09:52
Contrast-enhanced tomographic 3D ultrasound imaging of peripheral arterial disease and potential autologous bypass grafts
| Speaker: | Steven Rogers, Manchester, United Kingdom |
Coffee and visit to hands-on workshops
Time: 10:00 - 10:30
Coffee Symposium: The paclitaxel safety controversy - from patient-level data to big data: What the newest clinical evidence is telling us
Time: 10:03 - 10:28
| Chairing: | Peter Schneider, Honolulu, United States |
| Moderator: | Giovanni Torsello, Münster, Germany |
Time: 10:03 - 10:09
Patient-level data from the IN.PACT Clinical Programme: Is paclitaxel safe for the treatment of PAD?
| Speaker: | Peter Schneider, Honolulu, United States |
Time: 10:09 - 10:15
Two-year outcomes from four pooled multicentre RCTs: Safety after treatment with paclitaxel-coated balloons
| Speaker: | Thomas Albrecht, Berlin, Germany |
Time: 10:15 - 10:21
Big data: What does it tell us about survival following PAD revascularisation using drug technologies?
| Speaker: | Eric Secemsky, Boston, United States |
Paclitaxel debate
| Chairing: | Gunnar Tepe, Rosenheim, Germany |
| Moderator: | Thomas Zeller, Bad Krozingen, Germany |
Time: 10:30 - 10:40
CX Debate: DCB alone is enough for the popliteal segment
For the motion
Time: 10:30 - 10:35
| Marc Bosiers, Dendermonde, Belgium |
Against the motion
Time: 10:35 - 10:40
| Theodosios Bisdas, Athens, Greece |
Paclitaxel: The last word
| Chairing: | Roger Greenhalgh, London, United Kingdom |
| Moderators: | Andrew Holden, Auckland, New Zealand |
| Gunnar Tepe, Rosenheim, Germany | |
| Thomas Zeller, Bad Krozingen, Germany |
Review of the findings of the VIVA Forum
Time: 10:50 - 11:00
Paclitaxel summary of VIVA
| Speaker: | Gary Ansel, Columbus, United States |
The potential problem
Time: 11:10 - 11:20
My choices of DCB and DES data to combine in meta-analysis and my conclusions
| Speaker: | Konstantinos Katsanos, Patras, Greece |
Time: 11:20 - 11:27
BASIL 3 - withdrawal of paclitaxel use
| Speaker: | Jonathan Michaels, Sheffield, United Kingdom |
Time: 11:27 - 11:34
SWEDEPAD trials - withdrawal of paclitaxel use
| Speaker: | Marten Falkenberg, Gothenburg, Sweden |
Scrutiny of paclitaxel and the way forward
Time: 11:50 - 12:00
Statistical review of methodology and legitimacy of results
| Speaker: | Sue Duval, Minneapolis, United States |
Time: 12:00 - 12:10
Statistical issues
| Speaker: | Jon Deeks, Birmingham, United Kingdom |
Lunch and visit to hands-on workshops
Time: 12:30 - 13:30
Lunch Symposium: Optimising DCB results for long-term success
Time: 12:33 - 12:58
| Chairing: | Michael Lichtenberg, Arnsberg, Germany |
| Moderator: | Gary Ansel, Columbus, United States |
Time: 12:33 - 12:41
Long-term safety and efficacy update of a low-dose DCB
| Speaker: | Gary Ansel, Columbus, United States |
Time: 12:41 - 12:49
The benefits of IVUS in DCB treatment of the femoropopliteal segment
| Speaker: | Phillip Puckridge, Marion, Australia |
Time: 12:49 - 12:58
The value of effective vessel preparation before DCB use
| Speaker: | Theodosios Bisdas, Athens, Greece |
Review of paclitaxel usage: The way forward
| Chairing: | Roger Greenhalgh, London, United Kingdom |
| Moderators: | Andrew Holden, Auckland, New Zealand |
| Gunnar Tepe, Rosenheim, Germany | |
| Thomas Zeller, Bad Krozingen, Germany |
Time: 13:30 - 13:38
What the FDA are looking for in data requested
| Speaker: | Misti Malone, Silver Spring, United States |
Time: 13:38 - 13:46
What MHRA are looking for
| Speaker: | Hazel Randall, London, United Kingdom |
Time: 13:56 - 14:04
Paclitaxel early advances to limit restenosis
| Speaker: | Ulrich Speck, Berlin, Germany |
Time: 14:04 - 14:12
Paclitaxel: Why a chemotherapeutic was chosen to prevent restenosis - rationale and early experience
| Speaker: | Lindsay Machan, Vancouver, Canada |
Time: 14:12 - 14:20
Paclitaxel as primary therapy in oncology - benefits, doses, levels compared
| Speaker: | Erica Mayer, Boston, United States |
Time: 14:35 - 14:43
Lessons learned from the experience in the coronary arteries - sirolimus, paclitaxel and everolimus
| Speaker: | Bruno Scheller, Homburg, Germany |
Time: 14:43 - 14:51
Potential toxicity of paclitaxel in vascular interventions and pharmacokinetic aspects
| Speaker: | Aloke Finn, Gaithersburg, United States |
Time: 14:51 - 14:59
Paclitaxel effects on the human artery wall and insights from pathology
| Speaker: | Elena Ladich, Hollywood, FL, United States |
Tea and visit to hands-on workshops
Time: 15:30 - 16:00
Tea Symposium: Aortoiliac obstructive disease: Endoluminal solutions
Time: 15:33 - 15:58
| Chairing: | Michele Antonello, Padua, Italy |
Time: 15:33 - 15:39
Complexity of iliac occlusive disease, current treatment algorithm and treatment gaps
| Speaker: | Michele Antonello, Padua, Italy |
Time: 15:39 - 15:45
Challenging bilateral iliac case treated with a new balloon-expandable endoprosthesis
| Speaker: | Hany Zayed, London, United Kingdom |
Time: 15:45 - 15:51
Complex iliac occlusive disease: Treatment with covered stent grafts
| Speaker: | Gianmarco de Donato, Siena, Italy |
Edited case
| Chairing: | Michele Antonello, Padua, Italy |
Time: 16:00 - 16:30
Edited case: Treating iliac occlusive disease with a covered endoprosthesis
| Case presenter: | Andrew Holden, Auckland, New Zealand |
Interventional techniques
| Chairing: | Gunnar Tepe, Rosenheim, Germany |
| Moderator: | Robert Hinchliffe, Bristol, United Kingdom |
Time: 16:30 - 16:37
Advantages and results of treating SFA-popliteal occlusive lesions with a dual component stent: From the Austrian Registry
| Speaker: | Martin Werner, Vienna, Austria |
Time: 16:37 - 16:44
How to treat in-stent-restenosis in the femoropopliteal tract - what the literature tells us
| Speaker: | Marc Bosiers, Dendermonde, Belgium |
Time: 16:44 - 16:51
The case for spot stenting - similarities and differences between techniques
| Speaker: | Thomas Zeller, Bad Krozingen, Germany |
Edited case
Time: 16:51 - 17:21
Edited case: Focal dissection repair after femoropopliteal angioplasty
| Case presenter: | Michael Lichtenberg, Arnsberg, Germany |
Time: 17:21 - 17:28
Femoropopliteal bypasses with heparin-bonded PTFE are a durable treatment for long SFA-popliteal occlusions: When they are the best treatment and why
| Speaker: | Walter Dorigo, Florence, Italy |
Time: 17:28 - 17:40
Audience participation and discussion
Open bypass
Time: 17:40 - 17:50
CX Debate: In the absence of suitable venous graft material prosthetic bypass is the answer
For the motion
Time: 17:40 - 17:45
| Clement Darling III, Albany, United States | |
| CLICK HERE TO VIEW VIDEO |
Against the motion
Time: 17:45 - 17:50
| Andrew Holden, Auckland, New Zealand | |
| CLICK HERE TO VIEW VIDEO |